Effects of diclofenac and dexamethasone on horse experimental endotoxemia

Arquivo Brasileiro de Medicina Veterinaria e Zootecnia

Volumn 55, Issue 3, 2003, Pages 279-286

  Rosa, P C S ^a   Peiro J R ^b   Campebell, R C ^a   Valadao C A A ^b   Bechara, G H ^b  

^a Estudante Pos graduacao Esc Vet U   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Dexamethasone; Endotoxemia; Equine; Peritoneal fluid; Sodium diclofenac

Indexed keywords

DEXAMETHASONE; DICLOFENAC; ENDOTOXIN; GLUCOSE; PHOSPHATE;

ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FEVER; HORSE; INFUSION; INTERMETHOD COMPARISON; INTESTINE; LEUKOPENIA; LYMPHOCYTOPENIA; NEUTROPENIA; NONHUMAN; PERITONEAL FLUID; PROTEIN BLOOD LEVEL; RECTUM TEMPERATURE; STATISTICAL SIGNIFICANCE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS; ESCHERICHIA COLI;

EID: 4344640032     PISSN: 01020935     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-09352003000300006     Document Type: Article

References (44)

1. BAYSTON, K.F.; COHEN, J. Bacterial endotoxin and current concepts in the diagnosis and treatment of endotoxaemia. J. Med. Microbiol., v.31, p.73-83, 1990.
2. BROOKS, P.M.; HILL, W.; GEDDES, R. Diclofenac and ibuprofen in rheumatoid arthritis and osteoarthritis. Med. J. Aust., v.1, p.29-30, 1980.
3. BURROWS, G.E. Equine Escherichia coli endotoxemia: comparison of intravenous and intraperitoneal endotoxin administration. Am. J. Vet. Res., v.40, p.991-998, 1979.
4. CANNON, G.W.; CALDWELL, J.R.; HOLT P. et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib phase III protocol 035 study group. Arthritis Rheum., v.43, p.978-987, 2000.
5. CARGILE, J.L.; MACKAY, R.J.; DANKERT, J.R. et al. Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of Miniature Horses given endotoxin. Am. J. Vet. Res., v.56, p.1451-1459, 1995.
6. CECILIO, C.A., COSTA, E.H.; UCELLI, P. et al. The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids. Mediat. Inflamm., v.6, p.46-52, 1997.
7. CUNHA, F.Q.; FERREIRA, S.H. The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: inhibition by glucocorticoids. Europ. J. Pharmacol., v.129, p.65-76, 1986.
8. EWERT, K.M.; FESSLER, J.F.; TEMPLETON, C.B. et al. Endotoxin-induced hematologic and blood chemical changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Am. J. Vet. Res., v.46, p.24-30, 1985.
9. FRAUENFELDER, H.C.; FESSLER, J.F.; MOORE, A.B. Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes. Am. J. Vet. Res., v. 43, p.405-411, 1982.
10. HENRY, M.M.; MOORE, J.N. Equine endotoxemia. In: SMITH B.P. (Ed.). Large animal internal medicine. Saint Louis: Mosby Co., 1990. p.668-674.
11. HOLBROOK, T.C.; MOORE, J.N. Anti-inflammatory and immune support in endotoxemia and septicemia. Vet. Clin. North Am. Equine Pract., v.10, p.535-47, 1994.
12. INOUE, H.; UMESONO, K.; NISHIMORI, T. et al. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun., v.254, p.292-298, 1999.
13. KAWAI, S. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration. Inflamm. Res., v.47, p.S102-S106, 1998.
14. LAVOIE, J.P.; MADIGAN, J.E.; CULLOR, J.S. et al. Haemodynamic, pathological, haematological and behavioral changes during endotoxin injection in equine neonates. Equine Vet. J., v.22, p.23-29, 1990.
15. LEACH, M.; HAMILTON, L.C.; OLBRICH, A. et al. Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br. J. Pharmacol., v.124, p.586-592, 1998.
16. LOCHNER, F.K.. The use of allopurinol in an endotoxin shock model in the horse. 2nd Equine Colic Symposium, Athens, USA, p.50-53, 1986.
17. 2. Exp. Cell. Res., v.206, p.58-62, 1993.
18. MABIKA, M.; LABURN, H. The role of tumor necrosis factor-alpha (TNF-α) in fever and the acute phase reaction in rabbits. Europ. J. Physiol., v.438, p.218-223, 1999.
19. MAcKAY, R.J. Endotoxemia. In: ROBINSON, N.E. (Ed.). Current therapy in equine medicine. 3.ed. Philadelphia: W.B. Saunders Co., 1992. p.225-232.
20. MARTINEZ, L.L.; de OLIVEIRA, M.A.; FORTES, Z.B. Influence of verapamil and diclofenac on leukocyte migration in rats. Hypertension, v.34, p.997-1001, 1999.
21. MOORE, J.N. Introduction to endotoxemia. 41st AMERICAN ASSOCIATION EQUINE PRACT., USA, 1995. p.100-102.
22. MOORE, J.N. Recognition and treatment of endotoxemia. Vet. Clin. North Am. Equine Pract., v.4, p.105-113, 1988.
23. MOORE, R.M.; MUIR, W.W.; CAWRSE, M. et al. Systemic and colonic venous plasma eicosanoid and endotoxin concentrations, and colonie venous serum tumor necrosis factor and interleukin-6 activities in horses during low-flow ischemia and reperfusion of the large colon. Am. J. Vet. Res., v.56, p.656-663, 1995.
24. MORRESEY, P.R. Therapeutic intervention strategies in endotoxemia. Comp. Cont. Educ. Pract. Vet., v.23, p.925-931, 2001.
25. MORRIS, D.; MOORE, J.N.; CROWE, N. et al. Dexamethasone reduces endotoxin-induced tumor necrosis factor activity production in vitro by equine peritoneal macrophages. Cornell Vet., v.81, p.267-276, 1991.
26. MORRIS, D.D.; CROWE, N.C.; MOORE, J.N. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am. J. Vet. Res., v.51, p.1935-1940, 1990.
27. OCHALSKI, S.J.; HARTMAN, D.A.; BELFAST, M.T. et al. Inhibition of endotoxin-induced hypothermia and serum TNF-α levels in CD-1 mice by various pharmacological agents. Agents Actions, v.39, p.C52-54, 1993.
28. OLSON, N.C.; BROWN Jr., T.T. Dexamethasone-induced attenuationof cardiopulmonary dysfunction in endotoxemic calves. Am. J. Vet. Res., v.47, p.2187-2192, 1986.
29. + channels by diclofenac. Europ. J. Pharmacol., v.438, p.85-91, 2002.
30. PEIRÓ, J.R.; CAMPEBELL, R.C.; SANTANA, A.E. et al. Clinical and laboratory evaluation of horses after intraperitoneal injection of lipopolysaccharide (LPS). [published erratum appears in J. Equine Vet. Sci., v.20, p.44, 2000.] J. Equine Vet. Sci., v,19, p.185-189, 1999.
31. ROCHA, N.P.; FERREIRA, S.H. Restoration by levamisole of endotoxin-inhibited neutrophil migration, oedema and increased vascular permeability induced by carrageenin. Europ. J. Pharmacol., v.22, p.87-92, 1986.
32. ROTHWELL, N.J.; BUSBRIDGE, N.J.; LEFEUVRE, R.A. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol., v.69, p.1465-1469, 1991.
33. RUETTEN, H.; THIEMERMANN, C. Attenuation by calpain inhibitor I, an inhibitor of the proteolysis of IκB, of the circulatory failure and multiple organ dysfunctin caused by endotoxin in the rat. Br. J. Pharmacol., v.121, p.695-704, 1997.
34. SCHWARTZ, J.I.; CHAN, C.C.; MUKHOPADHYAY, S. et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther., v.65, p.653-660, 1999.
35. SKOUTAKIS, V.A.; CARTER, C.A.; MICKLE, T.R. et al. Review of diclofenac and evaluation of its place in therapy as a non-steroidal anti-inflammatory agent. Drug Intell. Clin. Pharm., v.22, p.850-859, 1988.
36. SUNDGREN-ANDERSSON, A.K; ÖSTLUND, P.; BARTFAI, T. IL-6 is essential in TNF-α-induced fever. Am. J. Physiol., v.275, p.R2028-R2034, 1998.
37. TEMPLETON, C.B.; BOTTOMS, G.D.; FESSLER, J.F. et al. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ. Shock, v.23, p.231-240, 1987.
38. TODD, P.A.; SORKIN, E.M. Diclofenac sodium, a reappraisal of its pharmacodynamic and pharmacokinetics properties, an therapeutic efficacy. Drugs, v.35, p.244-285, 1988.
39. VALADÃO, C.A.A.; PEIRÓ, J.R.; SANTANA, A.E. et al. Evaluation of peritoneal fluid in horses with experimental endotoxemia. J. Equine Vet. Sci., v.15, p.124-128, 1995.
40. WANECEK, M.; RUDEHILL, A.; HEMSÉN, A. et al. The endothelin receptor antagonist, bosentan, in combination with thecyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit. Care Med., v.25, p.848-57, 1997.
41. WARD, D.S.; BOTTOMS, G.D.: FESSLER, J.F. Prostaglandin, leukotriene, hematologic, blood chemical, and plasma enzyme alterations in chronic endotoxin shock in the pony: effects of flunixin meglumine. 2nd Equine Colic Symposium, Athens, USA, 1986. p.38-44.
42. WARD, D.S.; FESSLER, J.F.; BOTTOMS, G.D. et al. Equine endotoxemia: Cardiovascular, eicosanoid, hematologic, blood chemical, and plasma enzyme alterations. Am. J. Vet. Res., v.48, p.1150-1156, 1987.
43. WHITE, G.L.; ARCHER, L.T.; BELLER, B.K. et al. Increased survival with methyl-prednisolone treatment in canine endotoxin shock. J. Surg. Res., v.25, p.357-364, 1978.
44. ZETTERSTRÖM, M.; LUNDKVIST, J.; MALINOWSKY, D. et al. Interleukin-1-mediated febrile responses in mice and interleukin-1β activation of NF-κB in mouse primary astrocytes involves the interleukin-1 receptor accessory protein. Europ. Cytokine Netw., v.9, p.131-138, 1998.